During the first three quarters of 2023, these medicines helped the pharmaceutics research and development outfit top the GDP of its homeland, Denmark. This performance also catapulted Novo Nordisk to the top spot among European companies. Wegovy, the weight loss drug, raked in sales of $4.5bn, increasing the overall sales of this segment by 154%.…
Read more
Sales of Novo Nordisk’s (NVO) diabetic drug, Ozempic, escalated by more than $1bn between its $2.3bn in Q3 2022 and $3.5bn in Q3 2023. Yahoo Finance noticed the absence of any discussions around GLP-1s at two conferences. A JPMorgan analyst, who attended a healthcare conference in January 2024, viewed this as good news for the…
Read more
On Sunday, 17th December, industry experts noted that while the firm has grown rapidly in 2023, keeping momentum throughout 2024 will be noticeably harder, with investors predicting only a 9% upside on average for next year. Portfolio manager at Antipodes Partners, Nick Cameron, noted 2024 investor predictions: [Novo is] an excellent R&D company, and they’re…
Read more
This bullish stock performance follows on the heels of a key study that found Wegovy, the Novo Nordisk weight loss drug, reduces cardiac risks and related mortalities in obese people. Those involved in the study took the highest dose of the drug and consequently experienced a drop in blood sugar and inflammation, two of the…
Read more
The company indicated the trial would come to an end, approximately a year before scheduled completion, following a recommendation from an independent data monitoring committee. Ozempic, a treatment commonly used for Type 2 Diabetes, contains semaglutide. The trial aimed to discover if it could stem the progress of kidney disease and help with associated complications. …
Read more